The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in Medicaid: economic model update
Am J Manag Care. 2022 Dec;28(12):630-631. doi: 10.37765/ajmc.2022.89273.
1RxEconomics LLC, 11350 McCormick Rd, Executive Plaza II, Ste 705, Hunt Valley, MD 21031. Email: mcr@rxeconomics.com.
Abstract
Curative direct-acting antivirals for chronic hepatitis C provide a net economic benefit to Medicaid in less than 1 year. Cumulative savings to date have exceeded $15 billion.